Neurology, Public Health and Disability Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy.
Department of Neuroimmunology and Neuromuscular Disorders, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy.
Neurol Sci. 2017 Nov;38(11):1927-1931. doi: 10.1007/s10072-017-3083-6. Epub 2017 Aug 5.
The purpose of this study is to report on the validity, reliability, and sensitivity of the myasthenia gravis activities of daily living profile (MG-ADL) in a sample of Italian patients. Patients with myasthenia gravis (MG) completed a protocol that included the MG-ADL, the WHO Disability Assessment Schedule (WHODAS 2.0), the Besta Neurological Institute rating scale for myasthenia gravis, and the MG-composite. Cronbach's alpha was used to test reliability, Spearman's correlation and intra-class correlation coefficient (ICC) to test short-term test-retest, Kruskal-Wallis test to assess differences in MG-ADL between patients with different disease severity, and Wilcoxon signed-rank test to assess sensitivity to change. In total, 58 patients were enrolled: 44 were females, mean MG duration 10.5 ± 10.4 years, mean MG-ADL 3.98 ± 3.07. The MG-ADL showed good internal consistency (alpha = .774), stability (test-retest correlation = .98, ICC = .97). It was superior to the WHODAS 2.0 in differentiating patients with different MG type and severity (P < .001), it showed higher sensitivity to change (P = .001 for improved and P = .007 for worsened patients) and higher correlation with the MG-composite (RHO = .625). Our analysis shows that the Italian version of the MG-ADL is valid, reliable, stable, and sensitive to change.
本研究旨在报告重症肌无力日常生活活动量表(MG-ADL)在意大利患者样本中的有效性、可靠性和敏感性。重症肌无力(MG)患者完成了一项方案,其中包括 MG-ADL、世界卫生组织残疾评估表(WHODAS 2.0)、Besta 神经病学研究所重症肌无力分级量表和 MG 综合量表。Cronbach's alpha 用于测试信度,Spearman 相关系数和组内相关系数(ICC)用于测试短期重测信度,Kruskal-Wallis 检验用于评估不同疾病严重程度患者之间 MG-ADL 的差异,Wilcoxon 符号秩检验用于评估对变化的敏感性。共纳入 58 例患者:44 例女性,平均 MG 病程 10.5±10.4 年,平均 MG-ADL 3.98±3.07。MG-ADL 显示出良好的内部一致性(alpha=0.774)和稳定性(重测相关系数=0.98,ICC=0.97)。与 WHODAS 2.0 相比,它在区分不同 MG 类型和严重程度的患者方面具有优势(P<0.001),对变化更敏感(改善患者 P=0.001,恶化患者 P=0.007),与 MG 综合量表的相关性更高(RHO=0.625)。我们的分析表明,意大利版 MG-ADL 具有有效性、可靠性、稳定性和对变化的敏感性。